Scleroderma & PAH from interstitial lung disease prognosis Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 28 min 49 sec ✓ Published: 08-Oct-2010
Description: Chair: Barbara Smithson, BSN, RN nRhode Island Hospital nnVirginia Steen, MDnGeorgetown Univ., Washington D.C. nnTonya Zeiger, RRT nMayo Clinic, Jacksonville, Fla. nnThirty to fifty percent of patients with scleroderma or mixed connective tissue disease will go on to develop PAH, interstitial lung disease, or both. The development of PAH leads to a poor prognosis; therefore, all scleroderma patients need aggressive screening to rule out PAH and require treatment as soon as possible to arrest the
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)